UroGen Pharma (URGN) Q2 2024 earnings summary

Executive summary

• UGN-102 NDA submission is ahead of schedule, targeting low-grade, intermediate-risk non-muscle invasive bladder cancer, with a potential FDA decision as early as Q1 2025 if granted priority review.

• Phase 3 ENVISION trial for UGN-102 showed a 79.6% complete response rate at three months and an 82.3% 12-month duration of response, supporting its potential as a first-in-class therapy.

• JELMYTO net product revenue for Q2 2024 was $21.8 million, up from $21.1 million in Q2 2023, representing 16% sequential growth and 3% year-over-year growth.

• UroGen ended Q2 2024 with $241.3 million in cash, cash equivalents, and marketable securities, supporting operations and pipeline development.

• Recent equity offerings in June and July 2024 raised $123.6 million, strengthening the balance sheet for UGN-102 launch and business development.

Financial highlights

• Q2 2024 revenue: $21.8 million (Q2 2023: $21.1 million); gross profit: $19.6 million; gross margin approximately 90%.

• Net loss for Q2 2024 was $33.4 million ($0.91 per share), compared to $24.1 million ($1.03 per share) in Q2 2023.

• R&D expenses rose to $15.4 million, and selling, general, and administrative expenses increased to $30.1 million in Q2 2024.

• Cash, cash equivalents, and marketable securities totaled $241.3 million as of June 30, 2024.

• Operating loss for Q2 2024 was $25.8 million, versus $15.4 million in Q2 2023.

Outlook and guidance

• UGN-102 NDA submission expected imminently, with potential FDA approval in Q1 or Q2 2025 if granted priority review.

• Full-year 2024 JELMYTO revenue expected at the lower end of prior guidance; operating expenses at the higher end.

• Sufficient cash projected to support operations through profitability, including investments in UGN-103, UGN-104, and UGN-301.